Dr. Steven E. Finkelstein spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “Novel Radiopharmaceuticals for Prostate Cancer.”
Keywords: novel radiopharmaceuticals, prostate cancer[/su_tab]
How to cite: Finkelstein, Steven E. “Novel Radiopharmaceuticals for Prostate Cancer ” Grand Rounds in Urology. August 7, 2015. Accessed Nov 2024. https://dev.grandroundsinurology.com/prostate-cancer-steven-e-finkelstein-novel-radiopharmaceuticals-for-prostate-cancer/.
References
Bruland ØS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s.
http://www.ncbi.nlm.nih.gov/pubmed/17062709
Henriksen G, Breistøl K, Bruland ØS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002 Jun 1;62(11):3120-5.
http://www.ncbi.nlm.nih.gov/pubmed/12036923
Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008 Sep;38(5):358-66.
http://www.ncbi.nlm.nih.gov/pubmed/18662557
McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998 Sep;25(9):1341-51.
http://www.ncbi.nlm.nih.gov/pubmed/9724387
Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587-94.
http://www.ncbi.nlm.nih.gov/pubmed/17544845
Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature. 1977 Apr 14;266(5603):653-5.
http://www.ncbi.nlm.nih.gov/pubmed/859634
Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36.
http://www.ncbi.nlm.nih.gov/pubmed/21685461
Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012 Sep;30(5):607-13.
http://www.ncbi.nlm.nih.gov/pubmed/20888271
ABOUT THE AUTHOR
Steven E. Finkelstein, MD, FACRO, is a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida. He has served as a Co-Chair on the NRG Immunotherapy Committee, Co-Chair of the 2018-2019 ACRO Scientific Program Committee, and Chair of the SWOG Radiation STG Committee. He currently serves on the Board of Chancellors for ACRO. Dr. Finkelstein has also served as National Director of Translational Research Consortium (TRC), the cutting-edge therapy arm of 21st Century Oncology in Scottsdale, Arizona. Inspired by his grandmother, a cancer patient, he became a dedicated cancer surgeon who found that radiation therapy could sometimes do for his patients what surgery could not. Dr. Finkelstein received his medical degree from the University of Michigan Medical School. He served a residency in General Surgery at Washington University in Saint Louis, Missouri, and was Chief Resident in Radiation Oncology at the Moffitt Cancer Center in Tampa, Florida. Dr. Finkelstein also served fellowships in Biologic Immunotherapy, Clinical Cancer, and Surgical Oncology at the Surgery Branch of the National Cancer Institute in Bethesda, Maryland. He is a member of the American College of Radiation Oncology, the American Medical Association, the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.
